through the Integration of Biosensing and AI
Ultra-Precision Sensing Technology
Model BA200
Designed for non-invasive point-of-care assessment of airway inflammation, this device combines high-sensitivity biosensor technology (0.1 ppb) with full ATS/ERS compliance. It delivers multi-parameter results—FeNO, CaNO, FnNO—in under one minute, while a patented dual-channel design ensures complete protection against cross-contamination.
More
Driven by a passion for innovation and a commitment to excellence, desire to maintain high levels of innovation, knowledge, technical expertise, service.
Committed to providing solutions for respiratory diseases, cardiovascular diseases and metabolic diseases
Become a global provider in comprehensive chronic disease solution for both professional segment and homecare.
Chronic airway diseases—asthma, COPD, and bronchiectasis—are among the most common and burdensome respiratory conditions worldwide. They share overlapping symptoms such as cough, breathlessness, and sputum production, yet differ in unde...
FeNO and CaNO provide complementary rather than interchangeable information. FeNO is a composite signal reflecting predominantly central airway type 2 inflammation; it is measured at a single flow rate, is widely standardized, and has mat...
November 18, 2026 marks the 25th World COPD Day. This year’s theme, led by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is “Early Diagnosis and Management for a Better Life.” The message is delibera...
Please complete the form to contact our team